Table 2.

Metformin in the treatment of nonalcoholic fatty liver disease.

Author	n	Duration of treatment (months)	Transaminase reduction	Histologie improvement
Marchesini et al. (2001)	14	4	Yes	No data
Nair et al. (2004)	15	12	Yes but transient only	Yes; reduction in steatosis (3 of 10 cases) inflammation (2/10) and fibrosis (1/10)
Uygun (2004) (randomized controlled trial)	17	6	Yes	No
Bugianesi et al. (2005) (randomized controlled trial)	55	6	Yes	Yes; reduction in hepatic steatosis, inflammation and fibrosis; not all had follow histology
Schwimmer et al. (2005)	10	6	Yes	No data
Duseja et al. (2007)	7	6	Yes	No data